RxPONDER: sparing chemotherapy in node-positive early-stage breast cancer

(2:50)

RxPONDER: sparing chemotherapy in node-positive early-stage breast cancer

(3:8)

The RxPONDER trial and its impact on best clinical practice

(17:7)

Kalinsky discusses results from RxPONDER breast cancer clinical trial

(1:49)

Race and clinical outcomes in the RxPONDER trial

(2:34)

RxPONDER: 21-gene assay informs chemotherapy benefit in HR+ node-positive breast cancer

(38)

SABCS highlights: RxPONDER

(1:20)

DEBATE: \

(37:7)

RxPONDER: is it all OFS?

(3:42)

Oncotype DX Breast Recurrence Score Assay after TAILORx and RxPONDER: What’s Next?

(33:23)

RxPonder 2024 - AMH to determine the benefit of chemotherapy in early breast cancer.

(52)

Julie Gralow, MD, summarizes the RxPONDER trial from the 2020 San Antonio Breast Cancer Symposium

(5:7)

RxPONDER: chemotherapy and endocrine therapy in HR+/HER2- breast cancer

(1:26)

Node positive data - Exact Science

(2:12)

2021 West Oncology | Breast Cancer | Genomic Expression Panels - ESBC Chemotherapy Decision-Making

(16:7)

Important lessons from TAILORX, MINDACT and RX-PONDER:

(33:42)

Exact Sciences - Oncotype DX ® Test Can Help Certain Types of Breast Cancer Avoid Chemotherapy

(9:)

Treatment de-escalation in premenopausal patients with HR+/HER2- breast cancer and micro-metastasis

(54)

Hot topics at SABCS 2020

(2:57)

Can we decrease chemotherapy in LN+ premenopausal women based on genomic tests?

(1:47)